Latest News Keep up to date with the latest news and announcements from Theragnostics GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019Theragnostics will be at the Theranostics World Congress 2019February 20, 2019We are hiring! – Chief Medical Officer (application window now closed)February 19, 2019 News Archive GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019Theragnostics will be at the Theranostics World Congress 2019February 20, 2019 News Archive
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
